A Low Concentration of Tacrolimus/Semifluorinated Alkane (SFA)Eyedrop Suppresses Intraocular Inflammation in ExperimentalModels of Uveitis

Shyamasree De Majumdar, M Subinya, J Korward, A Pettigrew, D Scherer, Heping Xu

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
11 Downloads (Pure)

Abstract

Purpose: Corticosteroids remain the mainstay therapy for uveitis, a majorcause of blindness in the working age population. However, a substantial number ofpatients cannot benefit from the therapy due to steroids resistance or intolerance.Tacrolimus has been used to treat refractory uveitis through systemic administration. Theaim of this study was to evaluate the therapeutic potential of 0.03% tacrolimus eyedropin mouse models of uveitis.Methods: 0.03% tacrolimus in perfluorobutylpentane (F4H5) (0.03% Tacrolimus/SFA)was formulated using a previously published protocol. Tacrolimus suspended in PBS(0.03% Tacrolimus/PBS) was used as a control. In addition, 0.1% dexamethasone (0.1%DXM) was used as a standard therapy control. Endotoxin-induced uveitis (EIU) andexperimental autoimmune uveoretinitis (EAU) were induced in adult C57BL/6 mice usingprotocols described previously. Mice were treated with eyedrops three times/dayimmediately after EIU induction for 48 h or from day 14 to day 25 post-immunization (forEAU). Clinical and histological examinations were conducted at the end of theexperiment. Pharmacokinetics study was conducted in mice with and without EIU. Atdifferent times after eyedrop treatment, ocular tissues were collected for tacrolimusmeasurement.Results: The 0.03% Tacrolimus/SFA eyedrop treatment reduced the clinical scores andhistological scores of intraocular inflammation in both EIU and EAU to the levels similarto 0.1% DXM eyedrop treatment. The 0.03% Tacrolimus/PBS did not show anysuppressive effect in EIU and EAU. Pharmacokinetic studies showed that 15 min aftertopical administration of 0.03% Tacrolimus/SFA, low levels of tacrolimus were detectedin the retina (48 ng/g tissue) and vitreous (2.5 ng/ml) in normal mouse eyes, and thelevels were significantly higher in EIU eyes (102 ng/g tissue in the retina and 24 ng/ml inthe vitreous). Tacrolimus remained detectable in intraocular tissues of EIU eyes 6 h aftertopical administration (68 ng/g retinal tissue, 10 ng/ml vitreous). Only background levelsof tacrolimus were detected in the retina (2-8 ng/g tissue) after 0.03% Tacrolimus/PBSeyedrop administration.Conclusion: 0.03% Tacrolimus/SFA eyedrop can penetrate ocular barrier and reachintraocular tissue at therapeutic levels in mouse eyes, particularly under inflammatoryconditions. 0.03% Tacrolimus/SFA eyedrop may have therapeutic potentials forinflammatory eye diseases including uveitis.
Original languageEnglish
Pages (from-to)211-220
JournalCurrent Molecular Medicine
Volume17
Issue number3
DOIs
Publication statusPublished - 1 May 2017

Bibliographical note

Reference text: 1. Rosenbaum J.T., Martin T.M., Planck S.R. Anterior uveitis: clinical and research perspectives. Springer Semin. Immunopathol. 1999;21:135–145. [PubMed]

2. Hwang D.K., Chou Y.J., Pu C.Y., et al. Epidemiology of uveitis among the Chinese population in Taiwan: a population-based study. Ophthalmology. 2012;119:2371–2376. [PubMed]

3. Nussenblatt R.B. Immunoregulation of uveitis. Int. Ophthalmol. 1990;14:13–18. [PubMed]

4. Thorne J.E., Suhler E., Skup M., et al. Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis. JAMA Ophthalmol. 2016;134:1237–1245. [PubMed]

5. Rathinam S.R., Krishnadas R., Ramakrishnan R., et al. Population-based prevalence of uveitis in Southern India. Br. J. Ophthalmol. 2011;95:463–467. [PubMed]

6. Luger D., Silver P.B., Tang J., et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 2008;205:799–810. [PMC free article] [PubMed]

7. Luger D., Caspi R.R. New perspectives on effector mechanisms in uveitis. Semin. Immunopathol. 2008;30:135–143. [PMC free article] [PubMed]

8. Jaffe G.J., Martin D., Callanan D., et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–1027. [PubMed]

9. Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. 2005. [PubMed]

10. Sallam A., Taylor S.R., Habot-Wilner Z., et al. Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. Acta Ophthalmol. 2012;90:e323–e325. [PubMed]

11. Kino T., Hatanaka H., Hashimoto M., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. (Tokyo) 1987;40:1249–1255. [PubMed]

12. Sawada S., Suzuki G., Kawase Y., et al. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J. Immunol. 1987;139:1797–1803. [PubMed]

13. Peters D.H., Fitton A., Plosker G.L., et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs. 1993;46:746–794. [PubMed]

14. Kino T., Inamura N., Sakai F., et al. Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant. Proc. 1987;19:36–39. [PubMed]

15. Mochizuki M., Masuda K., Sakane T., et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behcet’s disease. Japanese FK 506 Study Group on Refractory Uveitis. Transplant. Proc. 1991;23:3343–3346. [PubMed]

16. Ishioka M., Ohno S., Nakamura S., et al. FK506 treatment of noninfectious uveitis. Am. J. Ophthalmol. 1994;118:723–729. [PubMed]

17. Kilmartin D.J., Forrester J.V., Dick A.D. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul. Immunol. Inflamm. 1998;6:101–109. [PubMed]

18. Hogan A.C., McAvoy C.E., Dick A.D., et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114:1000–1006. [PubMed]

19. Meinert H., Roy T. Semifluorinated alkanes--a new class of compounds with outstanding properties for use in ophthalmology. Eur. J. Ophthalmol. 2000;10:189–197. [PubMed]

20. Broniatowski M., Dynarowicz-Latka P. Semifluorinated alkanes--primitive surfactants of fascinating properties. Adv. Colloid Interface Sci. 2008;138:63–83. [PubMed]

21. Chen M., Muckersie E., Luo C., et al. Inhibition of the alternative pathway of complement activation reduces inflammation in experimental autoimmune uveoretinitis. Eur. J. Immunol. 2010;40:2870–2881. [PubMed]

22. Chen M., Copland D.A., Zhao J., et al. Persistent inflammation subverts thrombospondin-1-induced regulation of retinal angiogenesis and is driven by CCR2 ligation. Am. J. Pathol. 2012;180:235–245. [PubMed]

23. Xu H., Manivannan A., Dawson R., et al. Differentiation to the CCR2+ Inflammatory Phenotype In Vivo Is a Constitutive, Time-Limited Property of Blood Monocytes and Is Independent of Local Inflammatory Mediators. J. Immunol. 2005;175:6915–6923. [PMC free article] [PubMed]

24. Becker M.D., Garman K., Whitcup S.M., et al. Inhibition of leukocyte sticking and infiltration, but not rolling, by antibodies to ICAM-1 and LFA-1 in murine endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 2001;42:2563–2566. [PubMed]

25. Rosenbaum J.T., Woods A., Kezic J., et al. Contrasting ocular effects of local versus systemic endotoxin. Invest. Ophthalmol. Vis. Sci. 2011;52:6472–6477. [PMC free article] [PubMed]

26. Xu H., Koch P., Chen M., et al. A clinical grading system for retinal inflammation in the chronic model of experimental autoimmune uveoretinitis using digital fundus images. Exp. Eye Res. 2008;87:319–326. [PubMed]

27. Agarwal R.K., Silver P.B., Caspi R.R. Rodent models of experimental autoimmune uveitis. Methods Mol. Biol. 2012;900:443–469. [PMC free article] [PubMed]

28. Sloper C.M., Powell R.J., Dua H.S. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999;106:723–728. [PubMed]

29. Lee R.W., Greenwood R., Taylor H., et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology. 2012;119:1223–1230. [PubMed]

30. Zhang R., He R., Qian J., et al. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest. Ophthalmol. Vis. Sci. 2010;51:3575–3582. [PubMed]

31. Souza M.C., Fialho S.L., Souza P.A., et al. Tacrolimus-loaded PLGA implants: in vivo release and ocular toxicity. Curr. Eye Res. 2014;39:99–102. [PubMed]

32. Ishikawa T., Hokama H., Katagiri Y., et al. Effects of intravitreal injection of tacrolimus (FK506) in experimental uveitis. Curr. Eye Res. 2005;30:93–101. [PubMed]

33. Tamura S., Ohike A., Ibuki R., et al. Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J. Pharm. Sci. 2002;91:719–729. [PubMed]

34. Attas-Fox L., Barkana Y., Iskhakov V., et al. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr. Eye Res. 2008;33:545–549. [PubMed]

35. Fukushima A., Ohashi Y., Ebihara N., et al. Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. Br. J. Ophthalmol. 2014;98:1023–1027. [PMC free article] [PubMed]

36. Ghanem R.C., Vargas J.F., Ghanem V.C. Tacrolimus for the treatment of subepithelial infiltrates resistant to topical steroids after adenoviral keratoconjunctivitis. Cornea. 2014;33:1210–1213. [PubMed]

37. Barot R.K., Shitole S.C., Bhagat N., et al. Therapeutic effect of 0.1% Tacrolimus Eye Ointment in Allergic Ocular Diseases. J. Clin. Diagn. Res. 2016;10:NC05–NC09. [PMC free article] [PubMed]

38. Moscovici B.K., Holzchuh R., Chiacchio B.B., et al. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea. 2012;31:945–949. [PubMed]

39. Magalhaes O.A., Marinho D.R., Kwitko S. Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study. Br. J. Ophthalmol. 2013;97:1395–1398. [PubMed]

40. Dutescu R.M., Panfil C., Merkel O.M., et al. Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery. Eur. J. Pharm. Biopharm. 2014;88:123–128. [PubMed]

41. Yuan J., Zhai J.J., Chen J.Q., et al. Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration. J. Ocul. Pharmacol. Ther. 2009;25:345–350. [PubMed]

42. Fujita E., Teramura Y., Shiraga T., et al. Pharmacokinetics and tissue distribution of tacrolimus (FK506) after a single or repeated ocular instillation in rabbits. J. Ocul. Pharmacol. Ther. 2008;24:309–319. [PubMed]

43. Wallemacq P., Armstrong V.W., Brunet M., et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther. Drug Monit. 2009;31:139–152. [PubMed]

44. Treuting P.M., Dintzis S.M. Comparative Anatomy and Histology: A Mouse and Human Altas (Expert Consult). Academic Press; 2011. p. 474.

45. Gilger B.C. Ocular Pharmacology and Toxicology. 2014.

Keywords

  • Tacrolimus
  • semifluorinated alkane
  • uveitis
  • intraocular inflammation
  • eyedrop
  • pharmacolinetic

Fingerprint

Dive into the research topics of 'A Low Concentration of Tacrolimus/Semifluorinated Alkane (SFA)Eyedrop Suppresses Intraocular Inflammation in ExperimentalModels of Uveitis'. Together they form a unique fingerprint.

Cite this